基于PER.C6®无血清培养平台的Sabin株灭活脊灰疫苗在非人灵长类模型中具免疫原性与安全性
世界卫生组织建议开发使用减毒Sabin株的下一代 affordable 灭活脊灰疫苗(IPV)。本研究在鼠和非人灵长类(NHP)中评估基于PER.C6®细胞培养平台生产的三价Sabin-IPV(sIPV)的免疫原性与安全性。NHP按现行人类免疫程序接种不同稀释度疫苗,结果显示剂量依赖性免疫原性和良好耐受性,最低测试剂量诱导的中和抗体滴度不劣于商业sIPV,且与商业Salk IPV和sIPV免疫原性相当,无临床前安全信号。
要点
- PER.C6®平台sIPV在NHP中诱导的免疫原性与商业Salk IPV和sIPV相当。
- 三剂免疫后最低测试剂量(1、2、3型分别为5-7.5-25 D抗原单位)诱导的中和抗体滴度不劣于商业sIPV。
- 临床前未见安全信号,支持进一步开展临床试验。
核心结论
- 基于PER.C6®无血清培养平台的Sabin-IPV在鼠和NHP中显示剂量依赖性免疫原性和良好耐受性。
- NHP中该sIPV诱导的免疫原性与商业Salk IPV和sIPV可比,且无临床前安全信号。
- 该平台生产的sIPV可能成为实现和维持全球脊灰消灭所需 affordable 且具免疫原性IPV的一种解决方案。
研究设计与样本
- 在鼠和NHP中评估PER.C6®基Sabin-IPV的免疫原性与安全性。
- NHP按现行人类免疫程序(三剂基础免疫加一剂加强)接种四种不同剂量稀释度的疫苗。
- NHP同时接种商业可得的参考Salk IPV或sIPV作为对照。
主要发现
- 鼠和NHP中观察到剂量依赖性免疫原性和良好耐受性。
- NHP中三剂免疫后诱导抗Sabin病毒中和抗体滴度不劣于商业sIPV的最低测试剂量为1、2、3型分别5-7.5-25 D抗原单位。
- PER.C6®基sIPV在NHP中诱导的免疫原性与商业Salk IPV和sIPV疫苗相当。
关键数值与推荐
- NHP中最低测试剂量:1型5 D抗原单位、2型7.5 D抗原单位、3型25 D抗原单位,三剂后中和抗体滴度不劣于商业sIPV。
- NHP免疫程序为三剂基础免疫加一剂加强免疫,符合现行人类免疫程序。
临床怎么用
- 该临床前数据支持PER.C6®基sIPV进一步开展临床试验。
- 若临床验证成功,该平台可能为全球脊灰消灭提供可负担的IPV选择。
局限性
- 证据来自鼠和NHP临床前模型,尚未在人体中验证。
- 原文未报告具体样本量、P值和置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization recommends the development of affordable next-generation inactivated poliovirus vaccines (IPV) using attenuated poliovirus Sabin strains. Previously, we introduced a novel PER.C6® cell culture platform, which allows for high yield production of an affordable trivalent Sabin IPV vaccine. METHODS: Immunogenicity and safety of this novel PER.C6®-based Sabin-IPV (sIPV) was assessed in rats and non-human primates (NHPs). NHPs received one of four different dose dilutions vaccine according to current human schedule (three prime-immunizations and one boost immunization). For comparison, NHPs received commercially available reference Salk IPV or sIPV. RESULTS: Dose-dependent immunogenicity and good tolerability was observed for the PER.C6®-based sIPV formulations in rats and NHPs. In NHPs, the lowest tested dose that induced anti-Sabin virus-neutralizing antibody titers that were non-inferior to commercial sIPV after three immunizations was 5-7.5-25 D-antigen units for type 1, 2 and 3 respectively. DISCUSSION: PER.C6®-based sIPV induced comparable immunogenicity to commercial Salk IPV and sIPV vaccines in NHPs. Together with the absence of any preclinical safety signals, these data warrant further testing in clinical trials. sIPV produced on the PER.C6® cell platform could be one solution to the need for an affordable and immunogenic IPV to achieve and maintain global polio eradication.
引用
- Bockstal V, Tiemessen MM, Achterberg R, et al. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018. PMID: 30314910. doi:10.1016/j.vaccine.2018.09.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。